Who are Adhansia XR's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adhansia-xr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Adhansia XR — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adhansia XR (Adhansia XR) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine combined with alpha-2A adrenergic agonist. Area: Neurology / Psychiatry.

marketed Sympathomimetic amine combined with alpha-2A adrenergic agonist Dopamine transporter, norepinephrine transporter, alpha-2A adrenergic receptor Neurology / Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Adhansia XR (Adhansia XR) — Purdue Pharma LP. Adhansia XR is a combination of amphetamine salts and guanfacine that increases dopamine and norepinephrine activity while also activating alpha-2A adrenergic receptors to improve attention and reduce hyperactivity and impulsivity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adhansia XR TARGET	Adhansia XR	Purdue Pharma LP	marketed	Sympathomimetic amine combined with alpha-2A adrenergic agonist	Dopamine transporter, norepinephrine transporter, alpha-2A adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic amine combined with alpha-2A adrenergic agonist class)

Purdue Pharma LP · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adhansia XR — Competitive Intelligence Brief. https://druglandscape.com/ci/adhansia-xr. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing